Highlights

  • Atomo develops integrated rapid diagnostic devices for professional and home-testing settings.
  • Its blood-testing platforms combine sample collection and delivery within handheld devices.
  • Interlocked procedural steps are designed to limit common handling errors.
  • Its Curie platform focuses on simplifying swab-based sample processing.
  • Platform customisation and licensing are part of Atomo’s diagnostic partnership offering.

Atomo Diagnostics Limited (ASX:AT1) develops rapid diagnostic testing platforms designed to make sample collection, processing and result interpretation easier for users. Its technology integrates steps commonly performed with separate kit components, including collecting a blood sample and delivering buffer solution. For Atomo Diagnostics (ASX:AT1), device usability is central to its work with diagnostic developers seeking products suitable for clinics, point-of-care environments and self-testing. The business offers platform customisation, product development and technology licensing alongside its own rapid-test products.

Designing Around the Testing Procedure

Conventional lateral-flow tests can require users to operate multiple components in a fixed sequence. Missing a step, transferring the wrong volume of blood or handling buffer incorrectly can affect the process. Atomo Diagnostics (ASX:AT1) addresses these practical challenges through devices that combine components and guide the user through defined actions.

An integrated safety lancet, controlled blood delivery and interlocked steps feature across several AtomoRapid platforms. In certain models, the buffer is stored within the device and released through a built-in mechanism. These choices reduce the number of loose components handled during testing and are intended to support more consistent completion of the procedure.

How the Platforms Differ

AtomoRapid Pascal incorporates a safety lancet, a blood-collection and delivery system, and integrated buffer delivery. Its sequenced operation is intended for point-of-care and self-test applications. The Galileo platform also integrates blood collection with a safety lancet and controlled sample transfer. Both can be adapted to lateral-flow strips that use capillary blood.

For users performing tests outside clinical settings, Atomo Diagnostics (ASX:AT1) also offers the Elion platform, which integrates blood and buffer delivery with interlocked procedural steps. Curie takes a different route: it is designed for swab-based testing, consolidating sample extraction and delivery to remove manual dosing steps.

Partnerships and Product Development

The company's development services encompass device selection, feasibility assessment, prototyping, verification and support for manufacturing and regulatory submissions. Atomo Diagnostics (ASX:AT1) describes co-development, original-equipment manufacturing arrangements and technology licensing as routes through which partners can incorporate its platforms into diagnostic products.

Customisation matters because a diagnostic assay must be compatible with the cassette and sample-handling method used to deliver material to its test strip. The company's stated process includes evaluating user requirements before prototyping and undertaking validation before commercial rollout. Individual registrations do not approve every prospective assay.

Operational Considerations

An integrated device may simplify the user experience, but commercial deployment also depends on manufacturing quality, product-specific validation, regulatory requirements and partner demand. Atomo Diagnostics (ASX:AT1) operates in a field where devices can have different intended uses and regulatory classifications. The availability of a registered platform does not remove the need to assess new test configurations or relevant market requirements.

The company also offers digital support for self-testing and connectivity options for diagnostic workflows. Such capabilities can support instructions and reporting where implemented, although they are distinct from the core physical mechanisms for collecting and transferring samples.

Key Insights

Atomo Diagnostics (ASX:AT1) approaches rapid testing through the practical design of devices used by patients and healthcare professionals. Its integrated platforms address specific procedural tasks, while partnerships provide a way to adapt those platforms for different assays. The significance of its approach lies in the relationship between device usability, appropriate validation and the requirements of each testing setting—not in an assumed outcome for every diagnostic product.